BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

首席执行官

Mr. Kenneth Mulvany

员工

180

国家

卢森堡

ISIN

LU2355630455

WKN

000A3CTVP

上市

STU

2XA.STU

0 Comments

分享你的想法

FAQ

Odyssey Acquisition. 今天的股价是多少？▼

2XA.STU 当前价格为 €0.57 EUR，过去 24 小时上涨了 +7.2%。在图表上更密切关注 Odyssey Acquisition. 股价表现。

Odyssey Acquisition. 的股票代码是什么？▼

根据交易所不同，股票代码可能会有所不同。例如，在 Boerse Stuttgart 交易所，Odyssey Acquisition. 的股票以代码 2XA.STU 进行交易。

Odyssey Acquisition. 有多少名员工？▼

截至九月 04, 2026，公司共有180名员工。

Odyssey Acquisition. 属于哪个行业？▼

Odyssey Acquisition.从事于健康与养生行业。

Odyssey Acquisition. 何时完成拆股？▼

Odyssey Acquisition. 最近没有进行任何拆股。

Odyssey Acquisition. 的总部在哪里？▼

Odyssey Acquisition. 的总部位于卢森堡的 London。